Pramlintide
Symlin is an adjunct to mealtime insulin for specified diabetes patients, with a severe-hypoglycemia boxed warning.
Prescription-product label context
Symlin is an adjunct to mealtime insulin for specified diabetes patients, with a severe-hypoglycemia boxed warning.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Evidence and source limits
The Symlin label published in NIH DailyMed identifies pramlintide as an amylin analog for patients with type 1 or type 2 diabetes who use mealtime insulin and have not achieved desired glucose control despite optimal insulin therapy. This note follows the displayed label, revised December 2019 and checked October 10, 2026; it does not assert that every product has identical current labeling.
The label carries a boxed warning for severe hypoglycemia with insulin, particularly in type 1 diabetes. It lists hypoglycemia unawareness and confirmed gastroparesis among contraindications. Prescribing and insulin changes require a qualified healthcare professional.
This specific product and indication should not be reframed as approval of every amylin product, compounded preparation or general weight-loss claim. No dose, insulin-adjustment instructions, administration guidance or seller links are provided.
Original source: Pramlintide ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.